Loading...
In August 2026, the U.S. FDA approved an mRNA influenza vaccine (MFLUSIVA) to prevent seasonal influenza caused by virus subtypes A and B in adults aged 50 years and older.
Seasonal influenza causes outbreaks of varying severity each year, resulting in thousands of deaths and hospitalizations in the United States. mRNA vaccine technology offers the advantage of rapid manufacturing and has already been used successfully against Covid-19 and respiratory syncytial virus–related disease. The new vaccine, given as a single intramuscular dose, targets two influenza A strains (H3N2 and H1N1) and one influenza B strain.
Efficacy data for the approval came from an international industry-sponsored trial in which 41,000…